Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.46 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.46 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.44 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.44 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | HBB | P68871 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11040533 | 0.88 | LMNA (0.44) | LMNASMN1; SMN2CYP3A4CYP2D6MAPK3 | |
| SCHEMBL11159032 | 0.88 | LMNA (0.44) | LMNASMN1; SMN2CYP3A4CYP2D6MAPK3 | |
| SCHEMBL25965763 | 0.85 | LMNA (0.42) | LMNASMN1; SMN2CYP3A4CYP2D6MAPK3 | |
| SCHEMBL10656853 | 0.84 | LMNA (0.49) | LMNASMN1; SMN2CYP3A4CYP2D6MAPK3 | |
| SCHEMBL11098374 | 0.81 | LMNA (0.46) | LMNASMN1; SMN2CYP3A4CYP2D6MAPK3 | |
| SCHEMBL11024545 | 0.79 | LMNA (0.61) | LMNASMN1; SMN2CYP3A4CYP2D6MAPK3 | |
| SCHEMBL15616807 | 0.78 | LMNA (0.46) | LMNASMN1; SMN2CYP3A4CYP2D6MAPK3 | |
| SCHEMBL10656588 | 0.76 | LMNA (0.52) | LMNASMN1; SMN2CYP3A4CYP2D6MAPK3 | |
| SCHEMBL11739898 | 0.76 | LMNA (0.49) | LMNASMN1; SMN2CYP3A4CYP2D6MAPK3 | |
| SCHEMBL10459041 | 0.75 | LMNA (0.56) | LMNASMN1; SMN2CYP3A4CYP2D6MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230256109-A1 | Trans-Cyclooctene Bioorthogonal Agents and Uses in Cancer and Immunotherapy | TAMBO, INC. | 2023-08-17 | — | — | US | disclosed |
| US-20220168426-A1 | BIOORTHOGONAL COMPOSITIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-02 | — | — | US | disclosed |
| US-11253600-B2 | Bioorthogonal compositions | TAMBO, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20210128733-A1 | BIOORTHOGONAL COMPOSITIONS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230256109-A1 | Trans-Cyclooctene Bioorthogonal Agents and Uses in Cancer and Immunotherapy | ICOS, CD74, PBK | LMNA 4665/4885SMN1; SMN2 4078/4885CYP3A4 3169/4885 |
| US-20210128733-A1 | BIOORTHOGONAL COMPOSITIONS | TIE1, BBOX1, ST14 | LMNA 4462/4885SMN1; SMN2 2763/4885CYP3A4 2260/4885 |
| US-20220168426-A1 | BIOORTHOGONAL COMPOSITIONS | TIE1, BBOX1, ST14 | LMNA 4462/4885SMN1; SMN2 2763/4885CYP3A4 2260/4885 |
| US-11253600-B2 | Bioorthogonal compositions | TIE1, BBOX1, ST14 | LMNA 4462/4885SMN1; SMN2 2763/4885CYP3A4 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.